Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive
Papillary Thyroid Cancer With Highest Recurrence - PMC Back to Top Skip to main content NIH …

Importance BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its
role in PTC-related patient mortality has not been established. Objective To investigate the …

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

Importance BRAF V600E andTERTpromoter mutations can coexist in papillary thyroid
cancer (PTC). This genetic duet was indicated to be involved in the aggressiveness of PTC …

Thyroid cancer is rapidly increasing in incidence, but the mortality rate remains flat. Debate
has arisen over the need to detect or treat most thyroid cancers early, given their favorable …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …